Rucaparib (AG-014699) phosphate

For research use only. Not for use in humans.

目录号:S1098 别名: PF-01367338

Rucaparib (AG-014699) phosphate Chemical Structure

Molecular Weight(MW): 421.36

Rucaparib (AG-014699,PF-01367338)是一种PARP抑制剂,无细胞试验中作用于PARP1的Ki为1.4 nM,对其余8个PARP位点也有结合亲和力。Phase 3。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 1091.92 现货
RMB 980.68 现货
RMB 1730.04 现货
RMB 5483.69 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Rucaparib (AG-014699) phosphate发表文献61篇:

产品安全说明书

PARP抑制剂选择性比较

生物活性

产品描述 Rucaparib (AG-014699,PF-01367338)是一种PARP抑制剂,无细胞试验中作用于PARP1的Ki为1.4 nM,对其余8个PARP位点也有结合亲和力。Phase 3。
特性 AG-014699是第一个用于人类癌症疗法的PARP 抑制剂。
靶点
PARP [1]
(Cell-free assay)
1.4 nM(Ki)
体外研究

AG-014699有效抑制纯化的全长人类PARP-1,作用于LoVo和SW620细胞显示出强PARP抑制效果。AG-014699是AG14447的磷酸盐形式,且是第一个和temozolomide联用用于临床实验的PARP抑制剂。[1] AG-014699的辐射增敏性是由于下游NF-κB激活的抑制,及SSB修复抑制。AG-014699可以作用于DNA损伤激活的NF-κB,且克服传统NF-κB抑制剂的毒性,不会损害其他重要的炎症反应。[2]1μM AG-014699作用于D283Med细胞时抑制PARP-1活性达97.1%。[3]在NB-1691, SH-SY-5Y, 和SKNBE(2c)细胞中AG-014699明显增强Topotecan和Temozolomide的细胞毒性。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BT-474 MUfGeY5kfGmxbjDBd5NigQ>? MmK4NE4yNzFxNUCwM|ExODBibl2= MlHxbY5pcWKrdIOgVGFTWCCjY4Tpeol1gSCjdDDzeIFzfGmwZzDjc45k\XKwdILheIlwdiCxZjC1NFAhdk1? MUmyOVEzQDR3NR?=
BT474 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\yOVAxKG6P MVSxNQKBmzF3wrDk NI\6TI1z\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIITo[UBnd3W{IHzpcoV{KGGwZDDzbYdvcW[rY3HueIx6 MXyyOVEzQDR3NR?=
SKBR3 NYj3UZBoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPYOIU2ODBibl2= Ml3BNVDjiJNzNdMg[C=> M4jCcZJm\HWlZYOgZ4VtdCCpcn;3eIghcW5idHjlJIZwfXJibHnu[ZMh[W6mIIPp[45q\mmlYX70cJk> M2jvNVI2OTJ6NEW1
AU565 NVjsXottT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHYd2Q3PTByIH7N M4nwc|Ex6oDVMUZCpIQ> MkXSdoVlfWOnczDj[YxtKGe{b4f0bEBqdiC2aHWg[o92eiCuaX7ld{BidmRic3nncolncWOjboTsfS=> MXeyOVEzQDR3NR?=
EFM192A NHHMRllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWe1NFAhdk1? MXGxNQKBmzF3wrDk NWrSO5pMemWmdXPld{Bk\WyuIHfyc5d1cCCrbjD0bIUh\m:3cjDsbY5meyCjbnSgd4lodmmoaXPhcpRtgQ>? MmfhNlUyOjh2NUW=
MDA-MB-231 MWTGeY5kfGmxbjDBd5NigQ>? NHjvOGQyOC9{MD:0NEDPxE1? MVeyOEBp NHLQXVFqdmO{ZXHz[ZMheC2DS2SgcIV3\Wy|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MoXsNlQ1OjBzNUK=
MDA-MB-231 MW\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnvjNE4yNTRyIN88US=> NYHLV3JzOjRiaB?= M4j6VGlEPTEkgJm95qCKOTdwN{hCpO69VQ>? M1TaT|I1PDJyMUWy
MDA-MB-231 M17mTmFxd3C2b4Ppd{BCe3OjeR?= MlfRNVAwOjBxNECg{txO NHPvRmczPCCq Mo[3bY5lfWOnczDhdI9xfG:|aYOg[I9{\SCmZYDlcoRmdnSueR?= M1LEd|I1PDJyMUWy
MDA-MB-231 NETDTFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkX2NVAwOjBxNECg{txO NF;4Oo4zPCCq NIrMc|FjdG:la4OgZ4VtdCCleXPs[UBxem:pcnXzd4lwdiCrbjDHNk9OKHCqYYPl M4HEd|I1PDJyMUWy
H460 M3vxRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVq0NFAhdk1? MlLSNlTDqGh? M3:1dIlv[3KnYYPld{Bk\WyudXzhdkBz[WSrb4PlcpNqfGm4aYT5 NFTLOI0zPDRzMU[xNS=>
A549  NF;zcG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3SxTlQxOCCwTR?= NXi5TmtQOjUEoHi= NVXoXot[cW6lcnXhd4V{KGOnbHz1cIFzKHKjZHnvd4Vve2m2aY\peJk> NYn6dXZbOjR2MUG2NVE>
DT40 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTJzIH7N NWKyfmlqOjR|NU[4NVM>
DU145 M1e3bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnS2TWM2OD1zODDuUS=> M4L2S|I1OzV4OEGz
COLO704 M3nGfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXiTWM2OD1{LkWyJOKyKDBwNkeg{txO MU[yN|czQTRyMh?=
OVMANAb MoK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHhcJZKSzVyPUKuOVghyrFiMD6zPEDPxE1? NWXTN4NCOjN5Mkm0NFI>
OV177 Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfEU|ZDUUN3ME2yMlc5KMLzIECuO|Eh|ryP Mnv5NlM4Ojl2MEK=
OAW28 NEjmcZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfNUJRpUUN3ME2zMlYyKMLzIECuNlgh|ryP M2PhUFI{PzJ7NECy
OVSAHO M3fnRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2i3[WlEPTB;Mz62OEDDuSByLkOzJO69VQ>? NY\hXJQ1OjN5Mkm0NFI>
OVKATE M1jlNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\JTGtKSzVyPUOuOlQhyrFiMT63PUDPxE1? NXzEXmt5OjN5Mkm0NFI>
OVCAR3 NWHmVGF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M372U2lEPTB;Mz63OEDDuSByLkSwJO69VQ>? NH3ERXkzOzd{OUSwNi=>
PEO14 M13rTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof1TWM2OD1|Lki0JOKyKDBwN{[g{txO Ml3TNlM4Ojl2MEK=
A2780 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnyTWM2OD1|Lkm0JOKyKDBwMkWg{txO M3nKWFI{PzJ7NECy
OVTOKO MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTRwMUSgxtEhOS53MzFOwG0> NV22Om12OjN5Mkm0NFI>
KURAMOCHIb MlvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4DKXmlEPTB;ND6zOEDDuSByLkK5JO69VQ>? NWPkSlFGOjN5Mkm0NFI>
TOV21G MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTVwMEegxtEhOS5|MDFOwG0> MnrONlM4Ojl2MEK=
OVISE M4HFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnEb|ZKSzVyPUWuOlghyrFiMD6yN{DPxE1? Mnj2NlM4Ojl2MEK=
KK M2\Kd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7ZdnJiUUN3ME22MlE2KMLzIEGuOFIh|ryP NWPuXmRTOjN5Mkm0NFI>
RMUGS MmnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjoXJdKSzVyPUeuNFMhyrFiMT64N{DPxE1? NITKPHYzOzd{OUSwNi=>
PEO6 MljPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DCWmlEPTB;Nz6wOkDDuSByLke0JO69VQ>? NH;IR4QzOzd{OUSwNi=>
OVCA429 M{THVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVW1[llMUUN3ME24MlI6KMLzIEGuOlQh|ryP NXO3blhNOjN5Mkm0NFI>
OV167 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PLZWlEPTB;OD6zN{DDuSBzLkG4JO69VQ>? M3vjPVI{PzJ7NECy
RMG1 Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4r1OWlEPTB;OT6zNkDDuSB{LkO2JO69VQ>? M3\tb|I{PzJ7NECy
OVCAR5 MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmThTWM2OD17LkWwJOKyKDJwNUmg{txO MoTSNlM4Ojl2MEK=
EFO21 MmnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;2R2g2UUN3ME25MlkzKMLzIEGuPFch|ryP MlfTNlM4Ojl2MEK=
ES2 M{XRO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPtTWM2OD1zMD6xNkDDuSBzLkKzJO69VQ>? NHrNSokzOzd{OUSwNi=>
Tyk-nu NGfoZ|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mki5TWM2OD1zMD6yNEDDuSBzLkGyJO69VQ>? NEm0eFUzOzd{OUSwNi=>
CAOV3 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWKyboRuUUN3ME2xNE4{PyEEsTCwMlg4KM7:TR?= NUDnSYhGOjN5Mkm0NFI>
OV207 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TQWmlEPTB;MUKuNlchyrFiMD6zNkDPxE1? M3LLTlI{PzJ7NECy
HEY M{jCbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX7JR|UxRTF|LkCxJOKyKDBwN{Wg{txO NYnlTohQOjN5Mkm0NFI>
DOV13 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfhe21KSzVyPkG1JO69VQ>? MXSyN|czQTRyMh?=
EFO27 NF7sNGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjId4tKSzVyPkG1JO69VQ>? M2DUVlI{PzJ7NECy
HEY C2 M3Xvcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlf6TWM2OD5zNTFOwG0> NULCb3d5OjN5Mkm0NFI>
KOC-7cc NFvubWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFr2XXBKSzVyPkG1JO69VQ>? M2DqV|I{PzJ7NECy
MCASb M1SyUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHCNVFKSzVyPkG1JO69VQ>? M{fUSlI{PzJ7NECy
OAW42 NWjJb2h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRjF3IN88US=> MYqyN|czQTRyMh?=
OV2008 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfFfXdKSzVyPkG1JO69VQ>? NV\IXXBlOjN5Mkm0NFI>
OV90 M3vL[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2fLWWlEPTB-MUWg{txO NWTBZlhOOjN5Mkm0NFI>
OVCA420b NXjqTXBzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;6bIJWUUN3ME6xOUDPxE1? NYfUdIQ6OjN5Mkm0NFI>
OVCA432 NGi4S4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGm1VplKSzVyPkG1JO69VQ>? MYeyN|czQTRyMh?=
PEA2 M1P5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjTbJZKSzVyPkG1JO69VQ>? NViySng4OjN5Mkm0NFI>
SKOV3 NU\YOVU5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIS3WmdKSzVyPkG1JO69VQ>? NYiwcmZLOjN5Mkm0NFI>
TOV112D NY\aXFE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrTR2ExNTNizszN NEftTohKSzVyPkG1JO69VQ>? NXPUS29HOjN5Mkm0NFI>
C4-2 NXfr[21wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYCwMVMh|ryP NH\SS3UyPCCm NU\nSG9FTE2VTx?= M2fNTIRm[3KnYYPld{Bkd2yxbomgcpVu[mW{IHTvd4Uh\GWyZX7k[Y51dHl? Mme5NlM2PjV{NES=
PC3 M1z1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY[wMVMh|ryP MlLwNVQh\A>? NYrk[ldYTE2VTx?= MYPk[YNz\WG|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6 NXLEeIdROjN3NkWyOFQ>
DU145 M37hSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPhN4FIOC1|IN88US=> NYDUeYh2OTRiZB?= M2S0c2ROW09? NFjD[Xdl\WO{ZXHz[ZMh[2:ub375JI52dWKncjDkc5NmKGSncHXu[IVvfGy7 NH;G[JEzOzV4NUK0OC=>
VCaP  NHnDXXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPvNE0{KM7:TR?= NF\nSnoyPCCm NVX2WHJ5TE2VTx?= M{LrVYRm[3KnYYPld{Bkd2yxbomgcpVu[mW{IHTvd4Uh\GWyZX7k[Y51dHl? MUeyN|U3PTJ2NB?=
LNCaP  NHLzbZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF20Z2wxNTNizszN NYjqe4h3OTRiZB?= M4PzfWROW09? MWLk[YNz\WG|ZYOgZ49td267IH71cYJmeiCmb4PlJIRmeGWwZHXueIx6 MkH5NlM2PjV{NES=
MDA-MB-468 MUDD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1npbmlEPTB;OT63JO69VQ>? NEjQXlIzOjZ5OEG2NS=>
MDA-MB-231 MlfMR4VtdCCYaXHibYxqfHliQYPzZZk> MlzuTWM2OD1zMzFOwG0> M17kd|IzPjd6MU[x
Cal-51 MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MlH4TWM2OD16Lk[g{txO MlyzNlI3PzhzNkG=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
PAR; 

PubMed: 27960087     


MCF-7 cells were pretreated ± Rucaparib (15 µM, 2 hr), then ± Rucaparib (15 µM) or two different doses of β-lap (2.0 or 5.0 µM) for 2 hr. Levels of PAR (PARP hyperactivation) formation were assessed with α-tubulin as loading controls.

BRCA1; 

PubMed: 24085845     


MCF7 cells, MDA-MB-436 parental cells and resistant clones RR-1, RR-5, and RR-6 were treated with DMSO (−) or 1 µM rucaparib (+) for 24 h, and BRCA1 protein levels were assessed by using BRCA1 N- or C-terminal-specific antibodies by Western blot. 

27960087 24085845
Growth inhibition assay
Cell viability; 

PubMed: 31119062     


The effect of rucaparib on proliferation of keloid fibroblasts. (A) Keloid cell growth following treatment with rucaparib at various concentration (0, 2, 10, 20 μM) was evaluated by MTT assays. Data are expression as mean standard deviation of percent changes of triplicate optical densities. (B) Rucaparib (20 μM) significantly decreased proliferation of keloid fibroblasts. The combination of rucaparib (20 μM) and triamcinolone (50 μM) showed additive suppressive effect on keloid fibroblasts as compared with rucaparib single therapy. Data are expression as mean standard deviation of percent changes of triplicate optical densities. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide.

31119062
Immunofluorescence
α-tubulin; 

PubMed: 30589644     


Representative immunofluorescence images of DMSO-, rucaparib- (Ruca-), and Ola-exposed A549-ERCC1(WT/WT) and A549-ERCC1(–/–) cells. Cells were exposed to 15 μM Ruca or 40 μM Ola during 72 hours. White arrows, CCFs; yellow arrows, micronuclei. Scale bar: 20 μm. 

PAR; 

PubMed: 27515310     


Cells were treated with 20 mM hydrogen peroxide (H2O2) in order to stimulate PARP-1 activity in the presence or absence of the PARP-1 inhibitors rucaparib and olaparib. Poly(ADP-ribose) (PAR) chain synthesis was detected using an anti-PAR monoclonal Alexa Fluor 488-conjugated antibody (green). The nucleus was visualised using the nuclear counterstain DAPI (blue). Representative images obtained from the analysis of anti-PAR staining of SK-N-BE(2c) cells are shown.

γH2AX; 

PubMed: 23565244     


γH2AX foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells. 

53BP1; 

PubMed: 23565244     


53BP1 foci was determined by immunofluoresecence microscopy at 24 h following combined treatment with radiation and rucaparib in PC3 and LNCaP cells.

30589644 27515310 23565244
体内研究 AG-014699无毒,明显增强D384Med移植瘤DNA修复功能蛋白中temozolomide诱导的TGD。药物动力学研究显示在脑组织中也检测到AG-014699,说明AG-014699用于治疗颅内恶性肿瘤具有潜在可能。[3]活体模型(NB1691和SHSY5Y移植瘤)研究显示AG-014699增强temozolomide的抗癌活性,产生彻底且持久的肿瘤衰退现象。[4]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[3]
- 合并

激酶实验:

不同浓度(0到1μ)AG-014699作用于5×103D283Med 细胞,与只用DMSO处理5×103D283Med细胞相比,来测定PARP活性抑制率。参考GCLP验证试验的PAR标准曲线,在和NAD+及寡核苷酸(底物和激活剂)温育的6分钟期间,使用10H PAR抗体,通过PAR形成量的免疫检测,在细胞样本中测量最大程度刺激的PARP活性。
细胞实验: [3]
- 合并
  • Cell lines: D425Med, D283Med和D384Med细胞
  • Concentrations: 0.4 μM
  • Incubation Time: 3或5天
  • Method: 髓母细胞瘤细胞系包含D425Med, D283Med,和D384Med细胞,分别按1×103, 3×103,和3×103密度接种在96孔板上。接种24小时(D384Med细胞)或48小时(D283Med和D425Med细胞)后,细胞用不同浓度temozolomide处理。培养3天(D425Med和D384Med细胞)或5天(D283Med细胞)后,通过XTT细胞增殖检测试剂盒检测细胞活力。用DMSO处理的对照组和0.4μ AG-014699处理的实验组的百分比表示细胞生长。计算temozolomide单独使用或者和AG-014699联用时的GI50值。Temozolomide单独使用时的GI50值和与AG-014699联用时的GI50值之比就是趋化因子50(PF50)值。
    (Only for Reference)
动物实验:[3]
- 合并
  • Animal Models: 携带D283Med移植瘤的CD-1裸鼠
  • Dosages: 1 mg/kg
  • Administration: 腹腔注射,每天1次或4次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 84 mg/mL (199.35 mM)
Water Insoluble
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
10mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 421.36
化学式

C19H18FN3O.H3PO4

CAS号 459868-92-9
储存条件 粉状
溶于溶剂
别名 PF-01367338

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04179396 Recruiting Drug: Rucaparib|Drug: Enzalutamide|Drug: Abiraterone Metastatic Castration Resistant Prostate Cancer Clovis Oncology Inc. December 5 2019 Phase 1
NCT04171700 Recruiting Drug: Rucaparib Solid Tumor Clovis Oncology Inc. November 21 2019 Phase 2
NCT03954366 Active not recruiting Drug: Rucaparib|Drug: Rosuvastatin|Drug: Oral Contraceptives Neoplasms Clovis Oncology Inc. May 8 2019 Phase 1
NCT03824704 Active not recruiting Drug: Rucaparib|Drug: Nivolumab Epithelial Ovarian Cancer|Fallopian Tube Cancer|Primary Peritoneal Carcinoma|High Grade Serous Carcinoma|Endometrioid Adenocarcinoma Clovis Oncology Inc.|Bristol-Myers Squibb|Foundation Medicine May 15 2019 Phase 2
NCT03413995 Recruiting Drug: Rucaparib Prostate Cancer Metastatic Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins|Clovis Oncology Inc. September 10 2018 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

相关PARP产品

Tags: 购买Rucaparib (AG-014699) phosphate | Rucaparib (AG-014699) phosphate供应商 | 采购Rucaparib (AG-014699) phosphate | Rucaparib (AG-014699) phosphate价格 | Rucaparib (AG-014699) phosphate生产 | 订购Rucaparib (AG-014699) phosphate | Rucaparib (AG-014699) phosphate代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID